BLFS

Business Context and Reporting Period

Company: BioLife Solutions, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: BioLife develops and markets patented biopreservation media products (HypoThermosol and CryoStor platforms) for cells, tissues, and organs. The company serves cell therapy companies, pharmaceutical firms, cord blood banks, and toxicology testing markets. Products are serum-free, protein-free, and manufactured under Good Manufacturing Practices.

Key Financial Metrics

Note: Working Capital calculated as Current Assets ($1,168,198) minus Current Liabilities ($1,030,087).

Material Changes vs. Prior Period

• Revenue Growth: Product sales increased 31% ($69,915) for the quarter and 37% ($233,673) for the nine-month period compared to 2007, driven by higher sales to existing customers and new acquisitions in cell therapy and cord blood markets.
• Gross Margin Compression: Gross margin percentage declined from 69% to 57% (quarterly) and 62% to 43% (nine-month) due to higher production costs at the Contract Manufacturing Organization (CMO) compared to prior internal manufacturing.
• Expense Reductions: Sales and marketing expenses decreased 53% ($89,960) for the quarter due to lower headcount. General and administrative expenses increased 10% ($44,496) primarily due to legal fees associated with ongoing litigation.
• Manufacturing Transition: The company incurred $106,294 in one-time manufacturing start-up costs to transition from outsourced manufacturing back to internal production to reduce long-term costs.
• Debt Increase: Interest expense increased significantly (107% for the quarter) due to a higher average debt balance from the Secured Convertible Multi-Draw Term Loan Facility.

Guidance, Outlook, and Risks

• Liquidity and Going Concern: The company reported a stockholders' equity deficiency of $(4,384,400). Management states that continued access to the Multi-Draw Term Loan Note is required to fund operations for the next twelve months. There is no assurance that additional capital will be available if the facility is restricted or terminated.
• Financing Updates: Subsequent to the reporting period (October 2008), the loan facility was increased to an aggregate of $9,000,000, and an additional $600,000 was drawn.
• Operational Risks: Risks include significant revenue reductions, increased capital expenditures, rising operating costs, and adverse outcomes from current litigation.
• Future Capital Needs: The company expects to need additional capital to reach a sustainable level of positive cash flow. Failure to secure capital could prevent the company from continuing operations.
• Lease Expansion: In November 2008, the company signed an amended lease for additional clean room manufacturing space, increasing monthly rental obligations.

Investor Verification Checklist

• Debt Covenants and Conversion: Verify the terms of the Secured Convertible Multi-Draw Term Loan Facility, specifically the 85% conversion discount and the impact of potential equity financing on existing shareholders.
• Going Concern Status: Assess the reliability of the "going concern" assumption given the negative working capital and accumulated deficit exceeding $46 million.
• Manufacturing Transition Costs: Confirm the timeline and cost implications of transitioning back to internal manufacturing and whether the anticipated cost savings materialize.
• Litigation Exposure: Investigate the nature of the "ongoing litigation" cited as a driver for increased legal fees and a potential risk to financing.
• Revenue Concentration: Review customer concentration risks, as growth is attributed to specific markets (cell therapy, cord blood) which may be volatile.